Maria C. Bell
Expertise in
14
conditions

Dr. Maria C. Bell

Oncology
Sanford Obstetrics &Amp; Gynecology
414 N. 7th St., 
Bismarck, ND 
Accepting New Patients
Offers Telehealth
34 Years of Experience
Expertise in
14
conditions
Sanford Obstetrics &Amp; Gynecology
414 N. 7th St., 
Bismarck, ND 

Overview

Dr. Bell is a specialist in cancer of the female reproductive organs. The services she provides include: women's health and cancer screenings, gynecological surgery and administering chemotherapy. Dr. Bell prides herself on utilizing cutting edge technology to treat her patients. Speaks: English.

Dr. Bell is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Malignant Mixed Mullerian Tumor, Bladder Reconstruction, and Ureteroscopy.

Dr. Bell is board certified in American Board Of Obstetrics And Gynecology: Gynecologic OncologyAmerican Board Of Obstetrics And Gynecology: Obstetrics & Gynecology American Board Of Internal Medicine: Hospice & Palliative Care. She is actively involved in clinical research, co-authoring 23 peer reviewed articles and participating in 20 clinical trials. Dr. Bell is currently accepting new patients.

Specialties

Oncology

Licenses

Obstetrics & Gynecology in SD

Board Certifications

American Board Of Obstetrics And Gynecology: Gynecologic OncologyAmerican Board Of Obstetrics And Gynecology: Obstetrics & Gynecology American Board Of Internal Medicine: Hospice & Palliative Care

Fellowships

University of Alabama, Gynecologic Oncology

Hospital Affiliations

Sanford Medical Center Fargo
Sanford Medical Center Bismarck
Sanford Usd Medical Center
Sanford Medical Center Aberdeen

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Sanford
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Sanford Health
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 8 Less Insurance Carriers -

Locations

Sanford Obstetrics & Gynecology
414 N. 7th St., Bismarck, ND 58501
Other Locations
Sanford Broadway Clinic
801 Broadway N., Fargo, ND 58102
Sanford Gynecologic Oncology Clinic
1309 W. 17th St., Sioux Falls, SD 57104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Drug
Study Drug: Bupropion Hydrochloride
Study Phase: Phase 2
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Procedure, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 04, 2026
Intervention Type: Drug, Biological
Study Drugs: GEN-1, Carboplatin, Paclitaxel
Study Phase: Phase 1/Phase 2
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: March 24, 2026
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
Enrollment Status: Active_not_recruiting
Publish Date: December 30, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
View 9 Less Clinical Trials

23 Total Publications

Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Journal: JCO precision oncology
Published: July 15, 2026
Similar Doctors
Expertise in
71
conditions
Dr. Peter C. Kurniali
Oncology | Hematology
Expertise in
71
conditions
Dr. Peter C. Kurniali
Oncology | Hematology
Referral may be required

Sanford Cancer Center Bismarck

701 E. Rosser Ave., 
Bismarck, ND 
 (0.1 miles away)
701-323-5741
Languages Spoken:
English, Bahasa
See accepted insurances
Accepting New Patients

Dr. Peter Kurniali is a triple board-certified physician in internal medicine, hematology and oncology. He is active in research and teaches residents and medical students. He strives to provide compassionate care and cutting-edge medical management and treatment. Dr. Kurniali specializes in the treatment of: He also serves as an associate professor of medicine at the University of North Dakota School of Medicine & Health Sciences. Speaks: English, Indonesian. Dr. Kurniali is highly rated in 71 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Pleuropulmonary Blastoma, Lung Cancer, and Bone Marrow Aspiration. Dr. Kurniali is board certified in American Board Of Internal Medicine: HematologyAmerican Board Of Internal Medicine: Medical OncologyAmerican Board Of Internal Medicine: Internal Medicine. Dr. Kurniali is currently accepting new patients.

Expertise in
41
conditions
Dr. Thandiwe C. Gray
Oncology | Hematology
Expertise in
41
conditions
Dr. Thandiwe C. Gray
Oncology | Hematology
Referral may be required

Sanford Cancer Center Bismarck

701 E. Rosser Ave., 
Bismarck, ND 
 (0.1 miles away)
701-323-5741
Languages Spoken:
English, Swahili
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Gray is a member of the Edith Sanford Breast Center Physician Leadership Council, a physician-led, multidisciplinary group designed to help direct efforts for optimal breast health care. Speaks: English. Dr. Gray is highly rated in 41 conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, Breast Cancer, Angiosarcoma, and Inflammatory Breast Cancer. Dr. Gray is board certified in American Board Of Internal Medicine: Medical Oncology. Dr. Gray is currently accepting new patients.

Expertise in
55
conditions
Dr. Aaron L. Luebke
Hematology | Oncology
Expertise in
55
conditions
Dr. Aaron L. Luebke
Hematology | Oncology
Referral may be required

Sanford Cancer Center Bismarck

701 E. Rosser Ave., 
Bismarck, ND 
 (0.1 miles away)
701-323-5741
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Aaron Luebke specializes in hematology and oncology. He diagnoses and treats a variety of blood disorders and cancers, including: D r. Luebke approaches these conditions using the latest research and data-driven treatments. Speaks: English. Dr. Luebke is highly rated in 55 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Familial Colorectal Cancer, Penile Cancer, Lynch Syndrome, and Bone Marrow Aspiration. Dr. Luebke is board certified in American Board Of Internal Medicine: OncologyAmerican Board Of Internal Medicine: Internal Medicine. Dr. Luebke is currently accepting new patients.

Frequently Asked Questions about Dr. Maria C. Bell

How do I make an appointment with Dr. Maria C. Bell?

You can book an appointment with Dr. Maria C. Bell by calling their office at 701-323-5870. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Maria C. Bell a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Maria C. Bell is classified as an Elite expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Maria C. Bell specialize in?

While Dr. Maria C. Bell is a Oncology, they have specific expertise in Ovarian Cancer, Endometrial Cancer, and Malignant Mixed Mullerian Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Maria C. Bell participate in research or clinical trials?

Yes. Dr. Maria C. Bell has published 23 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. Maria C. Bell's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Maria C. Bell accept my insurance?

Dr. Maria C. Bell accepts most major insurance plans, including Blue Cross Blue Shield and Cambia Health Solutions. We recommend calling the office directly at 701-323-5870 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bell's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile